Vaishali Pharma Ltd. (VAISHALI) AI Stock Analysis

• Market Cap: ₹1.27B
• Dividend Yield: N/A
• Average Volume (3M): 431.60K
• Price to Earnings (P/E): 385.9
• Beta (1Y): 1.37
• Revenue Growth: 15.13%
• EPS Growth: -51.89%
• Country: IN
• Employees: 27
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.10
• Shares Outstanding: 107,192,130
• 10 Day Avg. Volume: 465,390
• 30 Day Avg. Volume: 431,596
• PEG Ratio: -11.89
• Price to Book (P/B): 0.26
• Price to Sales (P/S): 0.17
• P/FCF Ratio: -0.86
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹12.50
• Price Target Upside: 5.84% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 55 Neutral
• Price Target: ₹12.50 ▲(5.84% Upside)

The overall stock score of 55 reflects significant challenges in profitability and cash flow management, as well as a bearish technical outlook. While the company shows potential for revenue growth, improvements in operational efficiency and cash generation are crucial. The negative P/E ratio and lack of dividend yield further weigh on the stock's attractiveness.

Vaishali Pharma Ltd. Business Overview & Revenue Model

Company Description

Vaishali Pharma Limited engages in the pharmaceutical business in India and internationally. It offers active pharmaceutical ingredients (APIs), including antibiotics, anti-ulcer, anti-inflammatory/analgesic/anti-pyretic, anti-malarial, cardiac, anti-diabetic, anti-cold/anti-allergic, anti-diarrheal/anti-protozoal/anti-parasitic, anti-viral, anti-epileptic, anti-asthmatic, anti-fungal, anti-platelet agent, skeletal muscle relaxant, and anti-helmintic drugs, as well as excipients, topical steroids, corticosteroids, and enzymes. The company also provides formulation products, such as antibiotics/antibacterial, anti-platelet, laxative, anti-ulcer/enzyme, anti-asthmatic, anti-malarial, anti-cold/anti-allergic/anti-viral, anti-psychotic, anti-fungal, anti-inflammatory/analgesic/anti-pyretic, anti-diabetic, cardiac, vitamins, topical steroids/corticosteroids, and other formulations. In addition, it offers veterinary pharmaceutical, nutraceutical, oncology, herbal, and surgical products. The company was founded in 1989 and is headquartered in Mumbai, India.

How the Company Makes Money

Vaishali Pharma Ltd. generates revenue through the sale of its diverse portfolio of pharmaceutical and nutraceutical products. The company makes money primarily by manufacturing and selling finished pharmaceutical formulations and APIs to various healthcare providers, hospitals, and pharmacies. Additionally, Vaishali Pharma engages in export activities, supplying its products to international markets, which contributes significantly to its revenue stream. The company may also enter into strategic partnerships or distribution agreements to expand its market reach and enhance its earnings potential.

Vaishali Pharma Ltd. Financial Statement Overview

Summary

Vaishali Pharma Ltd. shows strong revenue growth potential, yet faces hurdles in profitability and cash flow management. The balance sheet is stable, but operational efficiencies and cash generation need improvement to enhance financial stability.

Income Statement

Vaishali Pharma Ltd. has demonstrated strong revenue growth, with a notable increase from 2024 to 2025. However, the company faced challenges in profitability, as indicated by a negative EBIT in 2025. The gross profit margin has declined compared to previous years, reflecting cost pressures. Net profit margin remains positive but is not improving significantly, which suggests moderate profitability.

Balance Sheet

The balance sheet shows a healthy equity base with a steady increase in stockholders' equity. The debt-to-equity ratio is moderate, indicating a balanced approach to leveraging. However, the equity ratio has shown slight fluctuations, suggesting some variability in asset funding. Overall, the balance sheet reflects stability with potential for growth.

Cash Flow

The cash flow statement reveals challenges in operational cash generation, with a significant negative operating cash flow in 2025. Free cash flow has also turned negative, indicating issues in generating cash after capital expenditures. The company needs to improve its cash flow management to sustain operations and fund growth effectively.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2021	Dec 2020
Income Statement
Total Revenue	991.76M	990.26M	862.80M	696.63M	715.37M	523.08M
Gross Profit	103.53M	102.85M	118.64M	149.85M	80.36M	61.56M
EBITDA	13.31M	32.95M	31.71M	113.59M	86.44M	44.42M
Net Income	4.27M	8.17M	7.19M	66.03M	40.24M	10.46M
Balance Sheet
Total Assets	0.00	1.10B	799.56M	789.07M	816.24M	861.23M
Cash, Cash Equivalents and Short-Term Investments	11.43M	18.43M	15.78M	124.24M	11.62M	3.13M
Total Debt	0.00	123.18M	126.09M	147.36M	208.11M	178.50M
Total Liabilities	-677.63M	449.29M	371.16M	383.76M	552.70M	637.05M
Stockholders Equity	677.63M	649.16M	428.39M	405.31M	263.54M	224.19M
Cash Flow
Free Cash Flow	0.00	-197.36M	2.71M	7.83M	4.54M	18.85M
Operating Cash Flow	0.00	-194.31M	3.82M	10.80M	13.19M	20.11M
Investing Cash Flow	0.00	-2.92M	12.03M	2.82M	-8.47M	-1.10M
Financing Cash Flow	0.00	199.88M	3.23M	-17.32M	4.17M	-18.12M

Vaishali Pharma Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 11.81
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:VAISHALI, the sentiment is Negative. The current price of 11.81 is below the 20-day moving average (MA) of 12.08, below the 50-day MA of 12.30, and below the 200-day MA of 13.64, indicating a bearish trend. The MACD of -0.08 indicates Positive momentum. The RSI at 40.41 is Neutral, neither overbought nor oversold. The STOCH value of 14.04 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:VAISHALI.

Vaishali Pharma Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BAFNAPH	65 Neutral	₹4.14B	50.13	4.90%	―	2.36%	2924.94%
AAREYDRUGS	60 Neutral	₹2.23B	53.47	2.91%	―	-4.74%	-35.14%
BALPHARMA	60 Neutral	₹1.32B	15.58	9.32%	1.45%	-14.16%	10.85%
VAISHALI	55 Neutral	₹1.27B	385.95	―	―	15.13%	-51.89%
BIOFILCHEM	52 Neutral	₹679.76M	24.28	2.97%	―	-31.82%	341.44%
KREBSBIO	44 Neutral	₹1.52B	-5.62	18.42%	―	-31.91%	-38.46%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%